With the market steadily pushing above and beyond its all-time highs, it’s becoming increasingly difficult to find stocks with compelling valuations. With this in mind, we asked three of our contributors which stocks they think are still bargains that might be worth buying right now.
Category: Healthcare Industry
Mylan’s Government Connections Go Deeper Than Initially Reported
Mylan CEO Heather Bresch’s father sponsored a bill that made it easier for generic drugs to be substituted back in 1986. This helped Mylan become the largest generic manufacturer.
Rush Medical Center, Aurora’s Rush-Copley tie the knot
A $55 million surgical expansion is under construction June 15, 2016, at Rush-Copley Medical Center in Aurora. The hospital plans to expand specialty care in neurosciences, neonatal and women’s health as part of a closer partnership with Rush University Medical Center in Chicago.
Daily Dividend Report: PBA, PLCE, AMGN, SPLS, VGR
Pembina Pipeline announced today that its Board of Directors declared a common share cash dividend for March 2017 of $0.16 per share to be paid, subject to applicable law, on April 15, 2017 to shareholders of record on March 25, 2017. The Children’s Place, the largest pure-play children’s specialty apparel retailer in North America, today announced that its Board of Directors has approved a new $250 million share repurchase program and has increased the Company’s quarterly dividend to $0.40 per share from $0.20 per share.
Wednesday’s ETF with Unusual Volume: XT
The iShares Exponential Technologies ETF is seeing unusually high volume in afternoon trading Wednesday, with over 637,000 shares traded versus three month average volume of about 73,000. Shares of XT were trading flat on the day.
Snap Slumps 12%, Closes at Lowest Since IPO
Shares of Snap Inc slumped 12 percent on Monday and closed at their lowest level of the three sessions since the Snapchat owner’s soaring market debut last week. The $3.4-billion listing last Thursday was the hottest technology offering in three years, but the loss-making company’s lofty valuation and slowing user growth have raised eyebrows on Wall Street.
Gilead Executive Says Pharmacy Benefit Managers Keep Prices High
Gilead Sciences Inc.’s hepatitis C cure set off a firestorm of criticism over high drug prices in 2014 that hasn’t let up since. Now an executive says the company can’t cut the product’s price because middlemen who manage drug benefits would refuse to cover it.
Perrigo Joins Firms With Generic Drugs Under U.S. Glare
U.S. prosecutors are examining the prices of skin treatments made by Perrigo Co. and a handful of other companies as part of a sweeping criminal investigation into possible collusion in the generic drug business, according to a document filed in court this week.
Activist Investor Wins Control of Immunomedics Board Following Shareholder Vote
The newly reconstituted Immunomedics board is likely to start a search for a new CEO and could either renegotiate the IMMU-132 deal with Seattle Genetics or cancel it. Immunomedics shareholders elected Friday to install an activist slate of four new directors, bringing to a close a protracted fight for control of the biotech company.
Biotech Stock Mailbag: OncoSec Medical and the Quest to Turn Cold Tumors Hot
This week, I will take a closer look at a new approach in cancer immunotherapy from a tiny biotech company — OncoSec Medical . Before I get started, a word or two of caution: OncoSec is a micro-cap biotech company with a single-digit stock price and an enterprise value of just $2.7 million.
Is This The Best Biotech Play for 2017?
Last year, a political spotlight on drug pricing policies threatened the entire industry. Scandals at Mylan and Valeant Therapeutics did damage to the entire sector, sending the share prices of many biotech companies down.
Biotech Premarket Movers: Impax, Clearside Biomedical, Mylan
Shares of Impax Laboratories were down 19% to $11.50 in premarket trading on Wednesday after the company reported results and said it is not issuing 2017 guidance for total revenue and EPS because of ongoing revenue volatility in its generics unit. The Fort Washington, Pa.-based firm reported fourth-quarter adjusted earnings per share of 16 cents on revenue of $198.4 million.
Is Illumina On The Verge of a Breakout?
Illumina has been tracing out a narrow consolidation pattern for the last seven weeks. Yesterday’s impressive 4.25% gain, which was the second-best performance in the Nasdaq 100, may soon spark an end to this bullish pennant formation with a fresh rally leg.
‘Wait until you can’t take it, and buy. Then wait until you are euphoric, and sell.’
There’s a reason why this market’s so hard to kill — the rotations are endless and they are positive! Two weeks ago, you couldn’t give away the drug stocks. Now they are all things of beauty.
Merck Takes $1.9 Billion Charge on Hepatitis C Drug
Merck & Co. will take an impairment charge of $1.9 billion, after taxes, related to the development of a hepatitis C treatment, the company said in a filing Thursday.
A Few Names on my Radar on This Softness
Momentum has slowed for the second day in a row, but the tendency has been some late buying that produces a strong close. With overseas markets operating on Monday when the U.S. is closed, there may be a little reluctance to add new inventory.
Here Comes Pfizer’s Powerful Breakout
Shares of Pfizer gained over 2% on Wednesday, extending the rally off the late February low to 7.75%. This impressive move has lifted the stock back to within striking distance of a major resistance area.
Merck Stops Clinical Trial of Alzheimer’s Drug
This Thursday, Dec. 18, 2014, file photo shows the Merck logo on a stained glass panel at a Merck company building in Kenilworth, N.J. Merck & Co. reports financial results Thursday, Feb. 2, 2017.
Merck Alzheimer’s Drug Study Halted Early for Futility
Another Alzheimer’s disease drug has failed to help patients. This time, it’s verubecestat, a BACE inhibitor from Merck .
Teva Pharmaceutical Industries Ltd. Reports Q4 Improvement Thanks to Actavis Deal
Shares of the Israel-based drugmaker were hit hard in the second half of 2016. However, the company had a chance to report good news with the announcement of its fourth-quarter and full-year 2016 financial results.
Why Sage Therapeutics Jumped Today
Sage Therapeutics announced top-lineresults froma Phase 2 clinical trial study of SAGE-217, the company’s orally administereddrug that is being researched as a hopeful treatment of major depressive disorder . Data from the trial showed that SAGE-217 met the study’s primary endpoint, which was to evaluate that the drug was safe and well-tolerated by patients.
Teva Said to Consider Options for Branded Generics Unit
Israeli drugmaker Teva Pharmaceutical Industries Ltd. is weighing options including a sale of its branded generics products business as it works to reduce debt, according to people familiar with the matter. The business could be valued at several billion dollars, and Teva may also consider spinning off the unit, the people said, asking not to be identified because the deliberations are private.
Is Gilead Sciences Getting Ready for a Massive Acquisition?
Sinking earnings. Horrible outlook for this year. Perhaps the big biotech needs to develop an antidepressant — just to give to its shareholders.
Why Intercept Pharmaceuticals’ Latest News Caused the Stock to Jump
So when the companyannounced on Friday morning that it was making a significant change to its late-stage clinical study of obeticholic acid in treating NASH, investors were eager to find out what’s going on. Intercept’s phase 3 REGENERATE clinical trial initially had two co-primary endpoints: fibrosis improvement with no worsening of NASH and NASH resolution with no worsening of fibrosis.
Gilead’s Biggest Blockbusters Are Fading Fast, Biotech Warns
Gilead Sciences Inc.’s massive hepatitis C franchise is fading, the company warned Tuesday, projecting that sales this year could be just two-thirds of what investors had been expecting. Revenue from the company’s drugs for the viral infection will be $7.5 billion to $9 billion in 2017, Gilead said in a statement.
Earnings Preview: GlaxoSmithKline Likely to See Currency Boost; Advair Sales in Focus
GlaxoSmithKline reports fourth-quarter earnings Wednesday, with investors looking for guidance on the fate of its key Advair drug and the recent pace of organic growth for new products sales. GlaxoSmithKline Plc reports fourth-quarter earnings Wednesday, with investors looking for guidance on the fate of its key Advair drug in the U.S. and the recent pace of organic growth for new products sales.
Teva Loses CEO, Leaving Investors to Guess What’s Next
Teva Pharmaceutical Industries Ltd. announced the departure of its chief executive officer after just three years and said it would undertake a thorough review of its business, leaving the world’s largest generic-drug maker without a permanent leader following lowered profit forecasts that sent the share price plunging. CEO Erez Vigodman has stepped down, and Chairman Yitzhak Peterburg will hold the job on an interim basis while a search is conducted for a successor, the Petach Tikva, Israel-based company said in a statement late Monday.
Teva CEO Is Out After Being Hired to Turn Around Drugmaker
Teva Pharmaceutical Industries Ltd.’s Erez Vigodman will step down as chief executive officer, three years after being hired to turn around the Israeli drugmaker. Chairman Yitzhak Peterburg will serve as interim CEO while the company looks for a replacement, Teva said in a statement Monday.
3 Crucial Questions Gilead Sciences Should Answer Tuesday
It’s the most wonderful time of the quarter. The time when every business cracks open its books and tells us what’s going on.
California Sues Teva, Allergan for Allegedly Blocking Generic Competition to Lidoderm
The state of California has filed a civil suit against units of drugmakers Teva and Allergan , for allegedly obstructing generic competition to Lidoderm transdermal patches. The suit, filed in federal court in San Francisco, alleges a “pay-for-delay” deal between the companies and Endo Pharmaceuticals, which already had its Lidoderm product on the market and had made $825 million off of it in 2011.
Why The Medicines Company Rocketed Higher Today
Amgen’s PCSK9 inhibitor Repatha “significantly” reduced the risk of cardiovascular events — heart attacks, strokes, and the like — compared to placebo. Investors will have to wait until the American College of Cardiology meeting next month to find out how significant the reduction was.
Amgen beats Street 4Q forecasts
The Thousand Oaks, California-based company said it had net income of $2.59 per share. Earnings, adjusted for non-recurring costs, came to $2.89 per share.
Amgen Cholesterol-Lowering Drug Repatha Cuts Heart-Related Adverse Events in Big Study
The outcome of the so-called ‘FOURIER’ trial is extremely important for Amgen because the data will be used to lobby insurance companies to reimburse for Repatha. Amgen said Wednesday that its cholesterol-lowering drug Repatha achieved all efficacy endpoints in a closely watched clinical trial by reducing the risk of adverse cardiovascular events, including death.
Merck Matches Profit Expectations But Sales Come Up a Bit Short
Merck & Co. Inc. reported Thursday fourth-quarter earnings that rose to $1.18 billion, or 42 cents a share, from $976 million, or 35 cents a share, in the same period a year ago.
Pfizer Profit, Forecast Fall Short as Generics to Hurt Sales
Pfizer Inc. posted fourth-quarter earnings and a forecast for 2017 that were both short of analysts’ estimates, as the drugmaker said it will lose billions of dollars in revenue as products lose exclusive sales rights. Revenue in 2017 will be $52 billion to $54 billion, Pfizer said in a statement Tuesday, compared with the $54.3 billion average of analysts’ estimates compiled by Bloomberg.
Teva Plunges After U.S. Judge Invalidates Four Copaxone Patents
Teva Pharmaceutical Industries Ltd. plunged to the lowest in more than a decade following a U.S. court ruling that invalidated four patents on its best-selling multiple sclerosis drug Copaxone. The ruling, issued late on Monday, may open the door to generic competition for a drug that generates a fifth of Teva’s $20 billion in annual sales.
Related Article: There May Be a Buying Opportunity When Pfizer Shares Hit This Important Level
Shares of Pfizer have been on the decline, losing some 5% from its January 5 high of $33.61 a share. Shares of Pfizer have been on the decline, losing some 5% from its Jan. 5 high of $33.61 a share.
IEFA, EFU: Big ETF Inflows
Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the iShares Core MSCI EAFE ETF , which added 14,000,000 units, or a 4.5% increase week over week. Among the largest underlying components of IEFA, in morning trading today Teva Pharmaceutical Industries is down about 0.2%, and NXP Semiconductors is lower by about 0.2%.
3 Reasons Gilead Sciences Inc. Stock Could Rise
Here are three things that could get shares turned around. OK, so perhaps anything is a bit extreme.
Bristol-Myers Squibb Falls as It Cuts 2017 Outlook
Bristol-Myers Squibb on Thursday cut its guidance for 2017, saying it now expects adjusted earnings of $2.70 to $2.90 a share for the year, down from its previous guidance of $2.85 to $3.05. In the fourth quarter, the drugmaker posted earnings of $894 million, or 53 cents a share, compared with a loss of $197 million, or a loss of 12 cents, a year earlier.